In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("the Listing Regulations"), we wish to inform you ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zodiac-JRD-MKJ's board, on November 12, 2025, approved unaudited financial results for Q2 and H1 FY26 ended September 30, 2025, with a clean limited review report from auditor H G Sarvaiya & Co. Standalone Q2 revenue rose about 41% YoY to Rs. 877.72 lakhs, but standalone H1 revenue fell roughly 21% to Rs. 997.87 lakhs versus Rs. 1,269.19 lakhs a year ago. Standalone H1 net profit improved about 28% YoY to Rs. 41.42 lakhs, with EPS at Rs. 0.38. On a consolidated basis (including subsidiary VEM Plastic Moulding), H1 revenue was Rs. 2,307 lakhs and net profit was Rs. 88.88 lakhs (EPS Rs. 0.81). The company completed a rights issue of Rs. 2,286.32 lakhs in June 2025, lifting equity share capital from Rs. 517.72 lakhs to Rs. 1,097.57 lakhs. However, standalone operating cash flow was deeply negative at Rs. (2,555) lakhs due to working capital changes.
Mixed picture for shareholders: profitability improved YoY and a fresh equity infusion strengthens the balance sheet, but the sharp H1 revenue decline and large negative operating cash flow signal working capital stress that investors should watch closely. Short-term stock reaction may be neutral-to-negative given the weak H1 top line despite the PAT uptick.